文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

镰状细胞病基因治疗中动员与干细胞采集的挑战与局限

Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease.
PubMed 文献 · Blood Adv · 2025-01-01

本文讨论镰状细胞病(SCD)基因治疗中外周血干细胞动员与采集的挑战,指出尽管FDA已批准两种细胞药物,但获取足够细胞及缺乏标准化方案仍是重大障碍。工作组由NHLBI资助的Cure Sickle Cell Initiative召集,旨在识别相关认知空白以改进晚期细胞治疗。

要点

  • 获取足够细胞生成基因治疗产品是SCD细胞治疗的主要障碍。
  • 缺乏描述最佳预处理、动员和干细胞采集的标准化方案。
  • 输血医学在动员、采集及移植输血策略中起关键支持作用。

核心结论

  • 获取足够细胞及缺乏标准化动员采集方案是SCD基因治疗成功的重要障碍。

研究设计与样本

  • 本文为NHLBI资助的Cure Sickle Cell Initiative工作组针对SCD基因治疗动员与采集挑战的论述。

主要发现

  • SCD仍是全球数百万患者的高发病率、预期寿命缩短的溶血性贫血。
  • FDA批准两种细胞药物前,异基因造血干细胞移植是唯一标准治愈选择。
  • 输血医学通过标准或交换输血策略支持动员、采集及移植过程。

临床怎么用

  • 临床需关注SCD患者动员与采集足够干细胞以生成细胞基因治疗产品的挑战。
  • 输血医学应参与支持动员、采集及移植中的输血策略。

局限性

  • 原文未报告具体研究样本量、数值或统计结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sickle cell disease (SCD) is a hemolytic anemia that afflicts millions of people worldwide and continues to carry high morbidity and reduced life expectancy. Allogeneic hematopoietic stem cell transplantation was the only standard-of-care option for cure before the US Food and Drug Administration's approval of 2 cellular drugs. Transfusion medicine plays a pivotal role in supporting patients through mobilization and apheresis collection of peripheral blood stem cells and through transplant using standard or exchange transfusion strategies. Despite these advances, obtaining sufficient cells to generate a cellular gene therapy product and lack of standardized protocols that describe the optimal preparative regimen, mobilization, and collection of stem cells present a significant barrier to success. Our working group, convened as part of the National Heart, Lung, and Blood Institute-funded Cure Sickle Cell Initiative, sought to identify gaps in our understanding of these processes to improve advanced cell therapies for SCD.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tanhehco YC, Thibodeaux S, Shi PA, et al. Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease. Blood Adv. 2025. PMID: 41396678. doi:10.1182/bloodadvances.2025016054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。